Neurocrine Biosciences Inc
(STU:NB3)
€
153.15
-1.9 (-1.23%)
Market Cap: 15.37 Bil
Enterprise Value: 14.57 Bil
PE Ratio: 26.83
PB Ratio: 5.14
GF Score: 93/100 Neurocrine Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020 / 05:30PM GMT
Release Date Price:
€85.68
(+0.61%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome to Global Healthcare Conference. I'm Jeff Hung, one of the Biotech analysts. (Operator Instruction] For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions) So for this session, we have from Neurocrine Biosciences, CEO, Kevin Gorman; and CFO, Matt Abernethy. Welcome, guys.
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Welcome, Jeff, and thank you very much for the opportunity to speak here today.
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Yes. So for those who may not be familiar with Neurocrine, can you provide a brief introduction?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Certainly. And before I start, Matt and I will be making forward-looking
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot